Buy $5,000 of Cochlear shares today and it could be worth this much in 12 months

Find out what brokers tip for this ASX healthcare stock next.

Cochlear Ltd (ASX: COH) shares are up around 1% and changing hands at $141.96 a piece, at the time of writing on Wednesday morning.

The latest increase comes off the back of a 8% share price hike on Tuesday, following the company's latest FY26 results announcement.

Cochlear posted a 2% increase in sales revenue and a 22% decrease in its underlying net profit, which came in right at the top end of guidance.

There were some significant positives though. Cochlear's operating cash flow surged $130 million to $368 million, while free cash flow also improved substantially. The company also continued to invest aggressively in research and development, lifting R&D spending 15% as it accelerated work on its product pipeline.

Clearly investors were pleased with the results and its shares have kept climbing higher.

It's great news for the stock after Cochlear shares suffered a huge 41% one-day crash in late-April after the company downgraded its guidance figures. 

Since hitting a 10-year low of just $90 per share in late-April, Cochlear shares have now rebounded 52%. There is still a long way to go, however. The shares are now down around 46% for the year to date and are roughly 52% lower than this time last year.

The question now is, can Cochlear shares keep climbing higher?

A woman leans forward with her hand behind her ear, as if trying to hear information.

Image source: Getty Images

What do analysts tip next for Cochlear shares?

It's possible that brokers and analysts could revise their stance on Cochlear shares in coming days, following the company's FY26 update yesterday.

But at the time of writing, it looks like the experts are still on the fence about the outlook for the hearing implant company's shares over the next 12 months.

Many are now uncertain that Cochlear shares can stage a meaningful recovery over the next 12 months. And some believe the shares are now above fair value.

Market Index data shows the majority of brokers have a hold rating on Cochlear shares. The $116.08 average target price now implies a potential 18% downside from the current trading price.

TradingView data shows something similar, although the figures are a little less pessimistic. Again, the majority of analysts have a hold rating on the shares. The $139.21 average target price implies a potential 2% downside over the next 12 months, at the time of writing.

So, if I invest $5,000 into Cochlear shares today, what could it be worth in 12 months?

These forecasts suggest that a $5,000 investment into Cochlear shares today, could fall to somewhere around $4,100 to $4,900 by this time next year. That implies a loss of up to $900.

What could drive Cochlear shares higher?

It's been a difficult year for the medical hearing implant device company. Cochlear has suffered from a number of strong headwinds, including a sector-wide rotation away from ASX healthcare shares this year. 

Looking ahead, I still see Cochlear as a strong, globally dominant business with its long-term outlook intact. I think the steep sell-offs this year were overdone, and that the share price could quietly keep climbing higher.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Healthcare Shares

Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging

Telix Pharmaceuticals shares are in the spotlight after the FDA granted Fast Track for its BiPASS pre-biopsy prostate cancer imaging…

Read more »

Three scientists looking at a laptop in a lab.
Healthcare Shares

What would it take for CSL shares to return to $250?

The shares have already recovered strongly, so I wanted to see whether $250 is realistic.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Expert names 'undervalued' ASX 200 healthcare stock to buy today

A top fundie expects more outperformance from this resurgent ASX healthcare share.

Read more »

A gavel is placed on a stand on a desk with a legal representative wearing a suit in the background.
Healthcare Shares

Cochlear shares fall as investors face another setback

Cochlear shares are back in the red.

Read more »